Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
Incyte (Nasdaq:INCY) announced that key data from its dermatology portfolio, including five late-breaking oral presentations, will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam. The presentations focus on expanding treatment options for immune-mediated dermatologic conditions such as vitiligo, atopic dermatitis, hidradenitis suppurativa, and prurigo nodularis.
The data highlights Incyte's efforts to evaluate the efficacy and safety of ruxolitinib cream in new patient populations and deepen understanding of povorcitinib in immune-mediated dermatologic conditions. Key presentations include studies on ruxolitinib cream for vitiligo, atopic dermatitis in children, hidradenitis suppurativa, and cutaneous lichen planus. Additionally, a study on oral povorcitinib for prurigo nodularis will be presented.
Several ePosters will also be presented, focusing on the efficacy and safety of ruxolitinib cream and povorcitinib in vitiligo treatment.
Incyte (Nasdaq:INCY) ha annunciato che i dati chiave del suo portfolio dermatologico, inclusi cinque presentazioni orali di grande rilevanza, saranno presentati al Congresso 2024 dell'Accademia Europea di Dermatologia e Venereologia (EADV) ad Amsterdam. Le presentazioni si concentrano su ampliare le opzioni terapeutiche per le condizioni dermatologiche mediate dal sistema immunitario come il vitiligo, la dermatite atopica, l'idradenite suppurativa e il prurigo nodulare.
I dati evidenziano gli sforzi di Incyte per valutare l'efficacia e la sicurezza della crema ruxolitinib in nuove popolazioni di pazienti e approfondire la comprensione di povorcitinib nelle condizioni dermatologiche mediate dal sistema immunitario. Le presentazioni chiave includono studi sulla crema ruxolitinib per il vitiligo, la dermatite atopica nei bambini, l'idradenite suppurativa e il lichene planus cutaneo. Inoltre, sarà presentato uno studio su povorcitinib orale per il prurigo nodulare.
Saranno presentati anche diversi ePoster, focalizzati sull'efficacia e la sicurezza della crema ruxolitinib e del povorcitinib nel trattamento del vitiligo.
Incyte (Nasdaq:INCY) anunció que los datos clave de su cartera dermatológica, incluidos cinco presentaciones orales de gran relevancia, se presentarán en el Congreso 2024 de la Academia Europea de Dermatología y Venereología (EADV) en Ámsterdam. Las presentaciones se centrarán en ampliar las opciones de tratamiento para las condiciones dermatológicas mediadas por el sistema inmunológico, como el vitíligo, la dermatitis atópica, la hidradenitis supurativa y el prurigo nodular.
Los datos destacan los esfuerzos de Incyte para evaluar la eficacia y seguridad de la crema de ruxolitinib en nuevas poblaciones de pacientes y profundizar en la comprensión de povorcitinib en condiciones dermatológicas mediadas por el sistema inmunológico. Las presentaciones clave incluyen estudios sobre la crema de ruxolitinib para el vitíligo, dermatitis atópica en niños, hidradenitis supurativa y liquen plano cutáneo. Además, se presentará un estudio sobre povorcitinib oral para prurigo nodular.
También se presentarán varios ePosters, centrados en la eficacia y seguridad de la crema de ruxolitinib y de povorcitinib en el tratamiento del vitíligo.
Incyte (Nasdaq:INCY)는 중요한 다섯 개의 구두 발표를 포함하여 자사의 피부과 포트폴리오의 주요 데이터가 2024년 암스테르담에서 열리는 유럽 피부과 및 성병학 아카데미(EADV) Congress에서 발표될 것이라고 발표했습니다. 발표는 면역 매개 피부 질환에 대한 치료 옵션 확대에 초점을 맞추고 있으며, 여기에는 백반증, 아토피성 피부염, 화농성 한선염 및 결절성 가려움증이 포함됩니다.
이 데이터는 새로운 환자 집단에서의 ruxolitinib 크림의 효능과 안전성 평가와 면역 매개 피부 질환에서의 povorcitinib에 대한 이해 발전을 위한 Incyte의 노력을 강조합니다. 주요 발표에는 백반증, 아토피성 피부염, 화농성 한선염 및 피부 결절성 리켄에 대한 ruxolitinib 크림 연구가 포함됩니다. 또한, 결절성 가려움증을 위한 경구 povorcitinib에 대한 연구도 발표될 것입니다.
여러 ePoster도 발표되어, 백반증 치료에서의 ruxolitinib 크림과 povorcitinib의 효능 및 안전성에 중점을 두게 됩니다.
Incyte (Nasdaq:INCY) a annoncé que des données clés de son portefeuille dermatologique, y compris cinq présentations orales importantes, seront présentées au Congrès 2024 de l'Académie Européenne de Dermatologie et de Vénérologie (EADV) à Amsterdam. Les présentations se concentreront sur l'élargissement des options de traitement pour les conditions dermatologiques médiées par le système immunitaire telles que le vitiligo, la dermatite atopique, l'hydradénite suppurative et le prurigo nodulaire.
Les données mettent en lumière les efforts d'Incyte pour évaluer l'efficacité et la sécurité de la crème ruxolitinib dans de nouvelles populations de patients et approfondir la compréhension de povorcitinib dans les conditions dermatologiques médiées par le système immunitaire. Les présentations clés incluent des études sur la crème ruxolitinib pour le vitiligo, la dermatite atopique chez les enfants, l'hydradénite suppurative et le licheni planus cutané. En outre, une étude sur le povorcitinib oral pour le prurigo nodulaire sera présentée.
Plusieurs ePosters seront également présentés, axés sur l'efficacité et la sécurité de la crème ruxolitinib et de povorcitinib dans le traitement du vitiligo.
Incyte (Nasdaq:INCY) gab bekannt, dass wichtige Daten aus seinem dermatologischen Portfolio, einschließlich fünf bedeutender mündlicher Präsentationen, auf dem Kongress der Europäischen Akademie für Dermatologie und Venerologie (EADV) 2024 in Amsterdam vorgestellt werden. Die Präsentationen konzentrieren sich auf die Erweiterung der Behandlungsoptionen für immunvermittelte dermatologische Erkrankungen wie Vitiligo, atopische Dermatitis, hidradenitis suppurativa und nodularen Juckreiz.
Die Daten heben die Bemühungen von Incyte hervor, die Wirksamkeit und Sicherheit von Ruxolitinib-Creme in neuen Patientengruppen zu bewerten und das Verständnis von Povorcitinib bei immunvermittelten dermatologischen Erkrankungen zu vertiefen. Zu den entscheidenden Präsentationen gehören Studien zur Ruxolitinib-Creme bei Vitiligo, atopischer Dermatitis bei Kindern, Hidradenitis suppurativa und kutanem Lichen planus. Darüber hinaus wird eine Studie über orales Povorcitinib bei nodulärem Juckreiz präsentiert.
Es werden auch mehrere ePoster vorgestellt, die sich mit der Wirksamkeit und Sicherheit von Ruxolitinib-Creme und Povorcitinib bei der Behandlung von Vitiligo befassen.
- Incyte will present five late-breaking oral presentations at EADV 2024
- Data showcases potential expansion of treatment options for immune-mediated dermatologic conditions
- Studies evaluate ruxolitinib cream in new patient populations
- Research on povorcitinib for immune-mediated dermatologic conditions
- None.
“We’re excited to present five late-breaking oral presentations at this year’s congress, featuring data that could further expand treatment options for those living with immune-mediated dermatologic conditions, including vitiligo, atopic dermatitis, hidradenitis suppurativa and prurigo nodularis,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “The data highlight our ongoing efforts to evaluate the efficacy and safety of ruxolitinib cream in new patient populations, as well as deepen our understanding of povorcitinib in patients impacted by debilitating immune-mediated dermatologic conditions.”
Key abstracts from Incyte-sponsored programs include:
Late-breaking Oral Presentations
Vitiligo
Impact of Treatment Duration on Response Durability: A Post Hoc Analysis of the TRuE-V Long-Term Extension Study of Ruxolitinib Cream in Vitiligo
Abstract #8077. Session: D2T01.3: Late breaking news. Presentation Time: 9:15 – 9:30 a.m. ET (3:15 – 3:30 p.m. CET), September 26, 2024
Atopic Dermatitis
52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study
Abstract #8082. Session: D2T01.4: Late breaking news. Presentation Time: 10:00 – 10:15 a.m. ET (4:00 – 4:15 p.m. CET), September 26, 2024
Hidradenitis Suppurativa
Ruxolitinib Cream for Mild-to-Moderate Hidradenitis Suppurativa: 32-Week Data From a Randomized Phase 2 Study
Abstract #8071. Session: D2T01.3: Late breaking news. Presentation Time: 9:00 – 9:15 p.m. ET (3:00 – 3:15 p.m. CET), September 26, 2024
Prurigo Nodularis
Efficacy and Safety of Oral Povorcitinib in Patients With Prurigo Nodularis: 40-Week Results From a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Abstract #8081. Session: D2T01.3: Late breaking news. Presentation Time: 9:30 – 9:45 a.m. ET (3:30 – 3:45 p.m. CET), September 26, 2024
Lichen Planus
Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: Results From a Phase 2, Randomized, Vehicle-Controlled Study
Abstract #7974. Session: D3T01.4: Late breaking news. Presentation Time: 10:30 – 10:45 a.m. ET (4:30 – 4:45 p.m. CET), September 27, 2024
ePosters
Vitiligo
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo Through 2 Years in the TRuE-V Studies
Poster #P2983.
Characterizing Maintenance of Repigmentation in a Post Hoc Analysis of the TRuE-V Long-Term Extension Study of Ruxolitinib Cream in Vitiligo
Poster #P2984.
Effect of Povorcitinib on Achievement of VASI50 by Body Region in Patients With Extensive Nonsegmental Vitiligo: Post Hoc Analysis of a 52-Week Phase 2 Study
Poster #P3016.
Effect of Povorcitinib on Achievement of VESplus50 by Body Region in Patients With Extensive Nonsegmental Vitiligo: Post Hoc Analysis of a 52-Week Phase 2 Study
Poster #P3017.
Full session details and data presentation listings, please see the EADV 2024 Congress online program here: https://eadvapps.m-anage.com/eadvcongress2024/en-GB/pag/
About Opzelura® (ruxolitinib) Cream
Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the
In
Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in
Opzelura and the Opzelura logo are registered trademarks of Incyte.
About Povorcitinib (INCB54707)
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for vitiligo, hidradenitis suppurativa (HS) and prurigo nodularis.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the promise presented by that pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions and Incyte’s goal of improving the lives of patients, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240925048109/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
What are the key presentations from Incyte at EADV 2024 Congress?
Which dermatological conditions are addressed in Incyte's EADV 2024 presentations?
What treatments are being studied by Incyte for dermatological conditions?
When and where will the EADV 2024 Congress featuring Incyte's presentations take place?
